{'fraction_non_alphanumeric': 0.0299625468164794, 'fraction_numerical': 0.033707865168539325, 'mean_word_length': 4.873626373626373, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparative Study of Live, Attenuated Rubella Virus Vaccines During the Immediate Puerperium

Three live, attenuated rubella virus vaccines (HPV-77 DK129 HPV-77 DE and Cendehill) were given to 107 adult women within one week postpartum. Of these, 66 did not have rubella HI antibody before immunization while the remainder had titers of 1:10 or 1:20. Seroconversions were comparably high for each vaccine; there was no significant difference in the antibody levels attained. Joint pain was a common complaint in each group of susceptible women (40.9%). When assessed in terms of limitation-of-motion, swelling or duration, symptoms were most marked in DK12. and least severe among the Cendehill recipients. In one DK12 recipient, recurrences were noted, the last 8 months after inoculation. Of the 66 women who were initially seronegative, 2, both DK12 recipients, complained of joint symptoms severe enough to limit their ability to care for the newborn child. No detectable HI antibody was found in 18 infants from 4 to 11 months after the mother had been immunized.